Medacta Group (MOVE) Guidance summary

Guidance on key objectives

• FY26 revenue growth guidance cut to ~9% in constant currency from 10%–14%; adjusted EBITDA margin expected broadly in line with 2025, versus prior guidance for ~50 bps expansion, subject to unforeseen events.

• 2024–2027 outlook unchanged: revenue CAGR of 12%–15% in constant currency and gradual adjusted EBITDA margin improvement versus 2025 in constant currency, subject to unforeseen events.

Market trends and strategic opportunities

• Growth expected at 2–3x the rate of operating markets; Europe and APAC continued at a solid pace despite softer U.S. conditions.

• U.S. procedure growth remained positive but moderated; expected H2 improvement did not materialize, and the reasons remain unclear.

• North American customer conversions remained strong, in line with historical levels and significantly above market growth; new surgeon interest and existing adopter activity support further potential.

• Each business line is targeted to grow faster than its respective market; the U.S. remains a key market for future development.

Strategic initiatives and plans

• Continued investment in U.S. commercial presence, people and local capabilities; Tennessee headquarters and manufacturing capacity plans signal long-term commitment.

• Parcus Medical acquisition strengthened the sports medicine offering and expanded access to U.S. customers and the ASC channel.

• Growth plans rely on the established product portfolio, continuous innovation and surgeon-specific education; portfolio launches planned for 2027 are expected to create opportunities over time.